CANONSBURG – Mylan Inc. said Thursday that it is now selling a generic version of Pfizer Inc.’s overactive bladder drug Detrol.
The Southpointe-based company said it started shipping its generic after receiving approval from the Food and Drug Administration. It said U.S. sales of Detrol, or tolterodine, totaled $61.5 million over the year ended Sept. 30.
Mylan plans to start selling a generic version of Detrol LA, a long-acting version of the drug, in early 2014 as part of an agreement with Pfizer. Annual U.S. sales of Detrol LA are around $600 million.
Shares of Pittsburgh-based Mylan rose 13 cents to $27.32 in midday trading after rising as high as $27.45 earlier in the session, its highest since October 2003.